Objective: Depression is common among patients diagnosed with cancer. Patients with cancer and depression use more health care services compared with nondepressed cancer patients. The current study seeks to estimate the added cost of depression in cancer patients in the first year after cancer diagnosis. Healthcare System. The annual health care charges for cancer patients with and without depression were analyzed using generalized linear models with a log-link function and gamma distribution, covarying for age, sex, race/ethnicity, comorbid diseases, and presence of metastatic disease. Total cost data were broken down into several categories including ambulatory care, emergency department visits, and hospital visits.
and with at least one health care claim within 1 year of the cancer diagnosis were included. To ensure complete annual health care costs for all patients, only those who survived a full year after their diagnosis were included in the primary analyses. A separate (subgroup) analysis was conducted using 703 patients who died prior to 1 year of health care data. All cancer sites were included except those for nonmelanoma skin cancer. The study was approved by the UC San Diego Institutional Review Board, and the project number was 160120. Waiver of consent was granted by the Institutional Review Board as the project met the requirements outlined in 45 CFR 46.116(d).
| Measures

| Health care costs
The charges incurred for relevant services in the UC San Diego Healthcare System were extracted from patients' EMR. Included charges were annual outpatient (ambulatory) office visits, ED visits, hospital visits, and mental health visits.
| Depression diagnosis
Depression diagnosis was extracted from the patients' EMR. Consistent with prior studies, 6, 10, [15] [16] [17] patients with an EMR ICD-9 diagnostic code of 296.2, 296.3, 300.4, or 311 were coded as "depressed." In addition, because subthreshold symptoms of depression are clinically important indicators of distress, particularly for newly diagnosed cancer patients, we elected to include codes 309.0, 309.1, 309.28. The inclusion of these codes has support in prior studies examining the impact of depression on health care costs.
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| Charlson Comorbidity Index
To assess each patient's severity of illness and the number of comorbidities, Deyo-Charlson Comorbidity Index (DCCI) score was calculated. 21 The DCCI is a useful predictor for physician visits, hospitalization, health service cost, and mortality. 10, [22] [23] [24] [25] Since, by definition, all patients in the current analysis had cancer, the value of "2"
was removed from each patient's overall score. In addition, the impact of metastatic cancer on health care costs was of interest in our analysis. Thus, for any patient with metastatic cancer, the DCCI assigned value of "6" for metastasis was subtracted from the overall score, and a separate variable for metastasis (1 = yes; 0 = no) was created and included in the analysis.
| Insurance coverage
We extracted insurance coverage from each patients' EMR for inclusion as a covariate in statistical analyses. Insurance was coded into 3 types: (1) Medi-Cal (California's Medicaid Program), (2) Medicare, and (3) Private Insurance. For the analyses, 2 dummy codes were created with "Medi-Cal" as the reference category.
| Data analysis
We performed 2 analyses. First, we compared demographic and health characteristics of the sample by depression status using chi-square and t tests for dichotomous and linear data, respectively. Second, because cost data are commonly represented by non-normal distribution with heavy right-skew, we estimated and compared health care costs for depressed and nondepressed patients using generalized linear models with a log-link function and gamma distribution. In this and less likely to be Asian (χ 2 = 34.02; df = 1; P < .001). Depressed patients also had significantly higher DCCI scores (t = 22.14; df = 1; P < .001) and were more likely to be diagnosed with a metastatic cancer (χ 2 = 63.08; df = 1; P < .001). No significant group differences were observed for age (t = 1.56; df = 1; P = .12). Also, participants in either group were not more likely to be of Black race (χ 2 = 3.35; df = 1; P = .07) or Hispanic ethnicity (χ 2 = 0.43; df = 1; P = .51) Table 1 .
| Total annual health care charges
Our primary analyses compared annual health care charges while covarying for age, sex, race/ethnicity, insurance type, cancer ranking, comorbid illnesses, and metastatic cancer. Table 2 reports results of these primary analyses. Depressed cancer patients had total annual health care charges that were 113% higher than nondepressed cancer patients (B = 0.76; Wald = 360.05; df = 1; P < .001). The estimated mean ± SEM charges for depressed patients were US $235 337 ± $8573 compared with $110 650 ± $1699 for nondepressed patients. P < .001) and other depressive disorders (B = 0.26; Wald = 37.62; df = 1; P < .001) significantly higher than no depression. Finally, inpatient charges were estimated at $200 327 ± $14 228 for the patients with major depression, $185 859 ± $6888 for the patients with other depressive disorders, and $128 261 ± $2512 for the patients with no depression. The costs for the major depression (B = 0.45; Wald = 36.33; df = 1; P < .001) and other depressive disorders groups (B = 0.37; Wald = 77.00; df = 1; P < .001) were again significantly higher than those for the no depression group.
| Subgroup analyses of deceased patients
Our subgroup analyses consisted of 703 patients. Of these, 174 
| Subgroup analyses by cancer site
Results of our analyses by cancer site are presented in Table S1 . As seen, the association of depression to total health care costs remained consistent across the majority of cancer sites, with neuroendocrine (P = .350), head/neck (P = .088), and hematologic (P = .065) cancers not reaching statistical significance.
| CONCLUSIONS
The findings of the present study expand the existing literature 13 to include an estimation of the difference in health care costs among cancer patients with vs without depression. We also provide new analyses of severity of depression and annual health care charges.
On the basis of a large data set, our study shows cancer patients with a depression diagnosis incurred total health care charges that are 113% greater than patients with no depression diagnosis. Similarly, we show that depressed cancer patients incurred significantly greater annual ambulatory health care charges, ED charges, and inpatient hospital costs. Interestingly, charges for high-cost cancer-related therapies either were not significantly different (ie, radiation) or were modestly higher (ie, chemotherapy) among depressed vs nondepressed cancer patients, suggesting that greater charges for depressed patients were not due entirely to more severe cancers or intense cancer-related treatments. We also demonstrated that patients with major depression diagnoses had annual health care charges nearly 3 times that of nondepressed patients and those with other depressive disorders had charges approximately double that of nondepressed patients. These results are consistent with prior research showing that depressed patients had significantly more annual non-mental health provider health care visits and were significantly more likely to have an ED visit and an overnight hospitalization than nondepressed patients.
To date, there is a paucity of data cost impact of depression in cancer patients. On the basis of a report using Truven MarketScan of claim data from commercial insurers and the Medicare 5% sample data (2004-2014), the annual cost of actively treated colon cancer was about $130 000 and $65 000 per patient per year, respectively.
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For cancer patients who received chemotherapy infusion therapy at outpatient hospital infusion centers, the per patient per year costs were about $160 000 and $60 000 (for both non-340B and 340B facilities), respectively. Although the baseline depression comorbidity was not detailed, these previously published data increase the generalizability of our findings given that the data parallel closely the charges presented for nondepressed patients in our sample. Similarly, in a study in which patients with cancer were not included, the annual cost incurred by patients with major depressive disorder was $10 379 versus $4391 for nondepressed patients, of which at least a 2-fold difference was observed. 17 Again, these trends parallel the findings of our research, in which there are 2-to 3-fold increases in health care use and costs for cancer patients with depression compared with those without.
| Clinical implications
Given the high cost of depression, this study lays the foundation for future evaluation of the health care cost savings attributed to adequate detection, prevention, and treatment for depression in cancer patients. Specifically, prevention or early treatment of depression could result in reducing the cost of care in cancer patients. Indeed, a systematic review showed that mental health prevention programs for noncancer patients are cost-effective. 27 Opportunistic screening in primary care for subthreshold depression in combination with minimal contact psychotherapy has been shown to be cost-effective in the prevention of major depression as well. 28 Tertiary treatment of depression via both psychological and pharmacological treatment is efficacious in managing depressive symptoms in both cancer 29 and noncancer patients, 30, 31 but no cost-effectiveness data currently exist.
Further studies are needed to evaluate of the effect of detection, treatment, treatment paradigm, timing, and quality of life improvement along with quantifying the economic impact of treatment on health care costs and service use. As the US health care system potentially moves toward a more interdisciplinary care model, collaborative care interventions for depression may be the key to deliver significant positive long-term impact in terms of quality of life and reduced health care service use and costs. 32 
| Strengths and limitations
The key strengths of our study were a large sample size and the use of EMR instead of paper chart and self-reporting. With the use of EMR, various components of care and cost are readily identified and retrievable via health informatics service because all service is coded electronically for billing and reimbursement purposes. Nevertheless, several limitations of this study should be discussed. Owing to the retrospective design, we could not ascertain true prevalence, incidence, and severity of depression based on ICD-9 code. In particular, the criteria used to diagnose depression may vary across providers and disciplines. Despite this limitation, it should be noted that the prevalence of depression in our study was 15.5%, consistent with other studies reporting a prevalence rates of 14% in inpatients and 16% in outpatients with cancer. 33 More prospective studies are needed that use clinical interview and/or validated depression scales to ascertain the current, 1-year, and lifetime prevalence of a depression diagnosis as well as current severity of depressive symptoms to determine the impact of these variations on health care costs and use.
Second, we could not ascertain critical information regarding cancer severity, notably stage and grade, both of which may be associated with a greater incidence of depression and could explain cost differences in the patients with vs without depression. Future research should collect and include information regarding disease severity to account for its influence on overall health care costs.
Third, this study was conducted in an academic cancer center that potentially sees patients with a higher severity of illness. Since our EMR system could only capture service and cost within the UC San Diego Healthcare System, we were unable to determine health care visits and costs of out-of-network health care providers. With the standardization of health information exchanges, future studies could potentially evaluate the health care cost of patients across multiple health care systems.
Fourth, although this study found depression to be associated with higher total health care costs in cancer patients, we did not have information on reasons that point to causality. We do not know if patients receive treatment for depression or their adherence to treatment since the EMR system is not linked to pharmacy records or outpatient claim data. In addition, we do not know how well other comorbidities were managed or the underlying severity of these conditions. Thus, it is difficult to evaluate the impact of these factors in our study.
Lastly, complete financial information was available beginning in 2014, so we could not determine if patients with high costs incurred prior to this year continued to incur high costs regardless of their depression status. Another limitation is "time-dependent confounding," where confounders (high cost) and risk factors (depression) mutually affect each other. Although our approach to depression was similar to several other studies, 6, 10, 12, 15, 20, [34] [35] [36] [37] [38] our study included potentially "mixed prevalent and incident depression cohorts" and rarely do these studies differentiate if depression was incident or prevalent. The estimated "average" total health care cost may therefore underemphasize effects related to onset of depression and may overemphasize effects of long-term depression. 39 In conclusion, we found significantly greater annual charges among depressed patients, encompassing outpatient/ambulatory care, inpatient hospital charges, and ED charges. However, charges for specific cancer-related treatments (ie, radiation) were not significantly different for depressed patients. Given the level of service use and cost in this population, a long-term, prospective study is warranted to evaluate the chronic impact of depression in cancer patients as well as the impact of mental health screening, prevention, and interventions on total health care costs.
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